Latest 10-K
View 10-KStock Information
OTCQB: CDXID
Price
Change
Volume
52 week Low/High
Day Low/High
Company Overview
Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. CDX-101, our astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, our zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. Our pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. We also have a commercial business unit that markets ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health. We sell ZanthoSyn® primarily through wholesale and e-commerce channels.
Contact Information
Investor Relations
Cardax, Inc.
T: (808) 457-1400
investors@cardaxpharma.com
Transfer Agent
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598